Stockscreener 앱 받기
9.71
0.61%
-0.06
시간 외 거래:
9.51
-0.20
-2.06%
전일 마감가:
$9.77
열려 있는:
$9.34
하루 거래량:
4.14M
Relative Volume:
0.76
시가총액:
$2.13B
수익:
$51.95M
순이익/손실:
$-265.94M
주가수익비율:
-6.7506
EPS:
-1.4384
순현금흐름:
$-216.89M
1주 성능:
+4.18%
1개월 성능:
+14.37%
6개월 성능:
-10.18%
1년 성능:
+25.61%
1일 변동 폭
$9.08
$9.85
1주일 범위
$9.06
$9.85
52주 변동 폭
$6.2301
$16.44
Ocular Therapeutix Inc Stock (OCUL) Company Profile
명칭
Ocular Therapeutix Inc
전화
781-357-4000
주소
15 CROSBY DRIVE, BEDFORD, MA
Compare OCUL vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OCUL
Ocular Therapeutix Inc
|
9.71 | 2.14B | 51.95M | -265.94M | -216.89M | -1.4384 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-09-15 | 개시 | Chardan Capital Markets | Buy |
| 2025-04-08 | 개시 | William Blair | Outperform |
| 2025-03-18 | 개시 | RBC Capital Mkts | Outperform |
| 2025-03-11 | 개시 | Needham | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-06-20 | 업그레이드 | TD Cowen | Hold → Buy |
| 2024-05-31 | 재개 | Piper Sandler | Overweight |
| 2024-02-09 | 개시 | BofA Securities | Buy |
| 2023-04-21 | 개시 | Robert W. Baird | Outperform |
| 2022-08-10 | 재개 | Berenberg | Buy |
| 2021-08-10 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-12-28 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-11-13 | 재확인 | Raymond James | Strong Buy |
| 2020-08-10 | 재확인 | H.C. Wainwright | Buy |
| 2020-03-03 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2019-05-21 | 다운그레이드 | Cowen | Outperform → Market Perform |
| 2019-05-21 | 재확인 | H.C. Wainwright | Buy |
| 2019-05-21 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2018-12-03 | 재확인 | Cantor Fitzgerald | Overweight |
| 2018-11-15 | 개시 | Raymond James | Strong Buy |
| 2018-09-07 | 개시 | Piper Jaffray | Overweight |
| 2017-10-24 | 개시 | Guggenheim | Buy |
| 2017-07-26 | 개시 | H.C. Wainwright | Buy |
| 2017-07-12 | 재확인 | Cantor Fitzgerald | Overweight |
| 2017-06-23 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2017-02-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2016-11-15 | 재확인 | RBC Capital Mkts | Outperform |
| 2016-08-11 | 개시 | JMP Securities | Mkt Outperform |
| 2016-02-17 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2015-10-23 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2015-08-13 | 개시 | Morgan Stanley | Overweight |
모두보기
Ocular Therapeutix Inc 주식(OCUL)의 최신 뉴스
Ocular Therapeutix reports Q1 EPS (40c), consensus (31c) - TipRanks
Ocular Therapeutix Q1 Earnings Call Highlights - Yahoo Finance
OCUL: AXPAXLI's phase III success in wet AMD drives NDA plans and commercial readiness, backed by strong cash reserves - TradingView
Ocular Therapeutix's Q1 Net Loss Widens, Revenue Rises - marketscreener.com
Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Earnings call transcript: Ocular Therapeutix Q1 2026 shows earnings miss By Investing.com - Investing.com Canada
Earnings call transcript: Ocular Therapeutix Q1 2026 shows earnings miss - Investing.com
Ocular Therapeutix Inc (NASDAQ:OCUL) Misses on Revenue and EPS in Q1 2026, Stock Dips - ChartMill
OCULAR THERAPEUTIX ($OCUL) Releases Q1 2026 Earnings - Quiver Quantitative
Earnings Flash (OCUL) Ocular Therapeutix Posts Q1 Loss $0.40 a Share, vs. FactSet Est of $0.31 Loss - marketscreener.com
Ocular Therapeutix (NASDAQ:OCUL) Reports Sales Below Analyst Estimates In Q1 CY2026 Earnings - TradingView
Ocular Therapeutix: Q1 Earnings Snapshot - marketscreener.com
Ocular Therapeutix 1Q 2026: Revenue $10.79M, Net income ($88.61M), EPS ($0.4) — 10-Q Summary - TradingView
[10-Q] OCULAR THERAPEUTIX, INC Quarterly Earnings Report - Stock Titan
Ocular Therapeutix reports Q1 2026: $10.8M revenue, $88.6M net loss, $666.7M cash - TradingView
OCUL: AXPAXLI's Phase 3 success in wet AMD drives NDA plans amid rising R&D costs and strong cash position - TradingView
Ocular Therapeutix (NASDAQ: OCUL) widens Q1 loss while advancing AXPAXLI Phase 3 trials - Stock Titan
MSN Money - MSN
Ocular Therapeutix Q1 2026 earnings preview - MSN
Ocular Therapeutix (OCUL) To Report Earnings Tomorrow: Here Is What To Expect - Yahoo Finance UK
Ocular Therapeutix earnings up next as AXPAXLI NDA looms By Investing.com - Investing.com South Africa
Ocular Therapeutix earnings up next as AXPAXLI NDA looms - Investing.com
OCULAR THERAPEUTIX, INC ($OCUL) CEO 2025 Pay Revealed - Quiver Quantitative
How Investors Are Reacting To Ocular Therapeutix (OCUL) Advancing AXPAXLI Toward NDA After Positive SOL-1 Trial - Yahoo Finance
Ocular Therapeutix (NASDAQ: OCUL) outlines 2026 proxy and 10M-share incentive plan increase - Stock Titan
[ARS] OCULAR THERAPEUTIX, INC SEC Filing - Stock Titan
Ocular Therapeutix Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI in Wet AMD - marketscreener.com
OCUL Stock Price, Quote & Chart | OCULAR THERAPEUTIX INC (NASDAQ:OCUL) - ChartMill
How The SOL-1 Readout Is Reframing The Story For Ocular Therapeutix (OCUL) - Yahoo Finance
OCUL stock surges overnight ahead of crucial wet AMD data readout, Sanofi takeover buzz builds - MSN
Ocular Therapeutix (OCUL) Begins Patient Enrollment in Axpali Tr - GuruFocus
Ocular Therapeutix Inc. (OCUL) Appears Highly Attractive Following SOL-1 Clinical Trial Data - Insider Monkey
Ocular Therapeutix enrolls first patient in wet AMD extension trial By Investing.com - Investing.com Australia
Ocular Therapeutix enrolls first patient in wet AMD extension trial - Investing.com
Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD - Yahoo Finance
Ocular Therapeutix™ to Participate in May Scientific and Investor Conferences - Sahm
Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026 - The Manila Times
May 5 at 8 a.m. ET: Ocular Therapeutix to discuss Q1 results - Stock Titan
Ocular Therapeutix gains amid takeover speculation - MSN
Ocular Therapeutix Says FDA Talks Progressing as It Eyes AXPAXLI NDA for Wet AMD on SOL-1 Data - MarketBeat
Ocular Therapeutix, Inc. $OCUL Stock Position Lessened by Deltec Asset Management LLC - MarketBeat
Ocular lines up May talks on AMD trial data and investor webcasts - Stock Titan
Ocular Therapeutix prices $475M stock offering - MSN
Avoiding Lag: Real-Time Signals in (OCUL) Movement - Stock Traders Daily
Ocular Therapeutix (OCUL) Is Up 8.2% After Positive Phase 3 AXPAXLI Data and FDA FeedbackWhat's Changed - Sahm
Assessing Ocular Therapeutix (OCUL) Valuation As AXPAXLI Prospects Drive A Wide Gap To Fair Value Estimates - Sahm
Ocular Therapeutix (OCUL) Quarterly Preview | Q4 2025: Profit SurprisesRevenue Diversification - Xã Thanh Hà
Ocular Therapeutix Inc (OCUL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.14%
0.48%
자본화:
|
볼륨(24시간):